Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stéphanie Cornen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Nature|October 4, 2019
Harnessing innate immunity in cancer therapyOlivier Demaria, Stéphanie Cornen, Marc Daëron, et al.
Nature|November 21, 2019
Publisher Correction: Harnessing innate immunity in cancer therapyOlivier Demaria, Stéphanie Cornen, Marc Daëron, et al.
Nature|February 21, 2024
Natural killer cell therapiesEric Vivier, Lucas Rebuffet, Emilie Narni-Mancinelli, et al.
Plos One|January 14, 2014
Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profilingStéphanie Cornen, Arnaud Guille, José Adélaïde, et al.
Cell|June 4, 2019
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor ImmunityLaurent Gauthier, Ariane Morel, Nadia Anceriz, et al.
Mabs|May 15, 2023
10th antibody industrial symposium: new developments in antibody and adoptive cell therapiesAna Antunes, Luis Alvarez-Vallina, Federico Bertoglio, et al.
Open Research Europe|August 30, 2023
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor controlMathieu Bléry, Manel Mrabet-Kraiem, Ariane Morel, et al.
Cell Reports. Medicine|October 19, 2022
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variantOlivier Demaria, Laurent Gauthier, Marie Vetizou, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Nature|October 4, 2019
Harnessing innate immunity in cancer therapyOlivier Demaria, Stéphanie Cornen, Marc Daëron, et al.
Nature|November 21, 2019
Publisher Correction: Harnessing innate immunity in cancer therapyOlivier Demaria, Stéphanie Cornen, Marc Daëron, et al.
Nature|February 21, 2024
Natural killer cell therapiesEric Vivier, Lucas Rebuffet, Emilie Narni-Mancinelli, et al.
Plos One|January 14, 2014
Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profilingStéphanie Cornen, Arnaud Guille, José Adélaïde, et al.
Cell|June 4, 2019
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor ImmunityLaurent Gauthier, Ariane Morel, Nadia Anceriz, et al.
Mabs|May 15, 2023
10th antibody industrial symposium: new developments in antibody and adoptive cell therapiesAna Antunes, Luis Alvarez-Vallina, Federico Bertoglio, et al.
Open Research Europe|August 30, 2023
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor controlMathieu Bléry, Manel Mrabet-Kraiem, Ariane Morel, et al.
Cell Reports. Medicine|October 19, 2022
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variantOlivier Demaria, Laurent Gauthier, Marie Vetizou, et al.
Pageof 1